Immunotherapy

Comparison of Adverse Events Between 2 Pembrolizumab Monotherapy Dosing Regimens

Kateryna Kovalenko, PharmD, BCOP; John Garrett, PharmD, MS, BCPS, BCOP, APh; Kathryn Bollin, MD; Harminder Sikand, PharmD, FCSHP, FASHP, FCCP; Leah Puglisi, MSc

The Effect of Dosing Schedule on the Incidence of Immune-Related AEs and Infusion Reactions in Patients Receiving Immunotherapy

Solmaz Karimi, PharmD, MS; April K.S. Salama, MD; Brent A. Hanks, MD, PhD; Beiyu Liu, PhD; Alaattin Erkanli, PhD; Theresa Brown, PharmD, BCOP, CPP

Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors

Nada Alsuhebany, BSPharm, PharmD, BCOP; Anastasia Graham, PharmD, MBA, BCOP; Erin Weeda, PharmD, BCPS; Amy Sion, PharmD, BCOP

Pancreatic Cancer: Review of the Current and Investigational Drug Landscape

Kevin H. Pang, PharmD; Valassia Antigone Theocharides; Yuxi Lei; Shivani K. Rana, BS; Richa K. Rana, BS; Mark H. Mansour; Meghana K. Ganjam; Jennifer Ahmed, PharmD

Complete Pathologic Response to Pembrolizumab in a Patient with Cutaneous Angiosarcoma: Case Report

Michael J. Nathenson, MD, and Jason L. Hornick, MD, PhD

Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies

Christopher Sinoimeri, PharmD; Bryan Do, PharmD, BCOP; Sheree Chen, PharmD, BCOP

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence

Abstract #CR10

Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis

Katherine P. Morgan, PharmD, BCOP, CPP; Yujiao Sun, PharmD; Allison Deal; Jared Weiss, MD; Amber Cipriani, PharmD, BCOP

Progression of Metastatic, PD-L1–Positive, Ampullary Carcinoma with a Treatment Holiday from Off-Label Use of Pembrolizumab Therapy

Hayley Heers, PharmD, BCPS; Amin Seyedkazemi, DO; Natalee Tanner, PharmD, BCOP; Madappa Kundranda, MD, PhD, FACP